US · REGN
Regeneron Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Tarrytown, NY 10591-6707
- Website
- regeneron.com
Price · as of 2025-12-31
$701.42
Market cap 81.22B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $491.47 | -29.93% |
| Intrinsic Value(DCF) | $326.90 | -53.39% |
| Graham-Dodd Method(GD) | $461.06 | -34.27% |
| Graham Formula(GF) | $391.36 | -44.21% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $106.49 | $76.94 | $1.90 | $0.00 | $0.00 |
| 2012 | $171.81 | $160.80 | $1,257.09 | $44.99 | $1,406.61 |
| 2013 | $325.91 | $328.87 | $1,244.89 | $36.63 | $222.99 |
| 2014 | $426.50 | $264.45 | $2,282.82 | $37.76 | $124.77 |
| 2015 | $374.59 | $283.20 | $2,188.33 | $59.32 | $285.65 |
| 2016 | $385.62 | $277.42 | $1,275.41 | $76.79 | $198.22 |
| 2017 | $339.41 | $278.56 | $410.07 | $104.72 | $289.81 |
| 2018 | $399.94 | $304.44 | $96.81 | $182.75 | $462.33 |
| 2019 | $491.11 | $302.50 | $59.52 | $198.43 | $116.76 |
| 2020 | $468.30 | $342.17 | $272.56 | $265.72 | $1,189.90 |
| 2021 | $638.27 | $628.41 | $2,721.43 | $559.56 | $7,139.59 |
| 2022 | $741.99 | $495.48 | $138.72 | $414.15 | $0.00 |
| 2023 | $962.33 | $562.67 | $231.79 | $428.69 | $577.71 |
| 2024 | $703.67 | $472.69 | $94.72 | $476.52 | $653.26 |
| 2025 | $790.81 | $491.47 | $6.78 | $461.06 | $391.36 |
AI valuation
Our deep-learning model estimates Regeneron Pharmaceuticals, Inc.'s (REGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $491.47
- Current price
- $701.42
- AI upside
- -29.93%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$326.90
-53.39% upside
Graham-Dodd
$461.06
-34.27% upside
Graham Formula
$391.36
-44.21% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| REGN | Regeneron Pharmaceuticals… | $701.42 | 81.22B | -30% | -53% | -34% | -44% | 18.36 | 2.65 | 5.77 | 13.20 | 224.20 | 2.76 | 85.35% | 24.95% | 31.41% | 14.87% | 12.73% | 11.50% | 0.09 | 81.69 | 4.13 | 3.28 | -0.07 | 819.00% | 99.00% | 1135.00% | 4.93% | 1.14 | 16.86% | 0.45% | 8.20% | 5.36% | 21.47 | 18.83 | 5.36 | 7.62 |
| ALNY | Alnylam Pharmaceuticals, … | $332.92 | 44.15B | +155% | +6,378% | -95% | -49% | 135.73 | 53.96 | 11.47 | 73.50 | — | 53.96 | 81.77% | 13.51% | 8.45% | 73.28% | -134.35% | 6.82% | 1.62 | 1.99 | 2.76 | 2.51 | -0.68 | -20688.00% | 6519.00% | -119273.00% | 1.09% | 0.36 | -128.40% | 0.00% | 0.00% | 5.06% | 81.65 | 88.00 | 11.03 | 5.93 |
| ARGX | argenx SE | $766.92 | 47.46B | -54% | +3,767% | -79% | +51% | 42.70 | 6.47 | 16.24 | 306.43 | — | 6.69 | 89.62% | -0.99% | 38.03% | 17.36% | -1.40% | 15.51% | 0.01 | -9.76 | 7.29 | 6.40 | -13.89 | -34767.00% | 7860.00% | -6746.00% | -0.42% | -0.12 | -9.76% | 0.00% | 0.00% | 0.00% | -1488.28 | -213.36 | 14.71 | 31.10 |
| CI | Cigna Corporation | $289.82 | 77.42B | -21% | +327% | -97% | +46% | 12.30 | 1.85 | 0.28 | 8.71 | 14.84 | -2.43 | 9.45% | 3.32% | 2.17% | 15.20% | 11.53% | 4.01% | 0.75 | 6.61 | 0.85 | 0.65 | 2.05 | 8292.00% | 1126.00% | -634.00% | 10.85% | 0.17 | 12.88% | 2.08% | 25.60% | 7.58% | 11.08 | 12.06 | 0.37 | 2.69 |
| COR | Cencora, Inc. | $372.14 | 72.39B | -33% | -64% | — | -63% | 41.92 | 43.58 | 0.20 | 19.29 | 734.06 | -4.12 | 3.16% | 1.14% | 0.48% | 145.58% | 42.46% | 2.18% | 7.13 | 8.69 | 0.90 | 0.51 | 1.70 | 571.00% | 931.00% | 699.00% | 4.88% | 0.07 | 53.77% | 0.67% | 27.90% | 1.33% | 19.76 | 22.47 | 0.22 | 4.91 |
| ELV | Elevance Health Inc. | $320.00 | 70.63B | -31% | -45% | -71% | +61% | 11.52 | 1.49 | 0.33 | 9.21 | — | 15.04 | 25.56% | 4.07% | 2.84% | 13.29% | 10.26% | 4.75% | 0.76 | 5.79 | 1.24 | 1.24 | 2.46 | -218.00% | 1262.00% | -3027.00% | 4.87% | 0.21 | 4.76% | 2.34% | 27.00% | 7.36% | 10.97 | 28.03 | 0.45 | 2.82 |
| GMAB | Genmab A/S | $29.44 | 18.14B | +21% | -15% | -44% | -6% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| IDXX | IDEXX Laboratories, Inc. | $656.73 | 52.44B | -34% | -40% | -88% | -64% | 48.13 | 31.77 | 11.85 | 35.33 | 213.11 | 47.15 | 61.80% | 31.60% | 24.62% | 66.20% | 45.37% | 31.89% | 0.67 | 35.54 | 1.17 | 0.76 | 0.61 | 2259.00% | 1042.00% | 3199.00% | 2.07% | 1.03 | 43.92% | 0.00% | 0.00% | 2.39% | 38.16 | 49.26 | 12.06 | 22.89 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| UTHR | United Therapeutics Corpo… | $503.90 | 22.79B | -28% | -44% | -38% | +9% | 17.05 | 3.21 | 7.15 | 11.66 | 130.50 | 3.26 | 87.92% | 46.89% | 41.94% | 19.71% | 25.78% | 17.51% | 0.00 | 76.54 | 6.60 | 3.40 | -0.86 | 1307.00% | 1061.00% | -369.00% | 4.57% | 2.78 | 23.09% | 0.00% | 0.00% | 5.10% | 14.21 | 20.38 | 6.66 | 20.45 |
| ZTS | Zoetis Inc. | $131.10 | 57.77B | -7% | -40% | -99% | -53% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
- CEO
- Leonard S. Schleifer
- Employees
- 15.16K
- Beta
- 0.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($326.90 ÷ $701.42) − 1 = -53.39% (DCF, example).